CRXT - CRXT STOCK NEWS

Clarus Therapeutics has appointed Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova brings nearly 30 years of experience in the pharmaceutical and biotech industry, previously leading clinical programs at Insmed and Pfizer. Her leadership is expected to enhance the clinical development of Clarus’ androgen and metabolic therapy pipeline, including potential orphan indications. Clarus aims to address unmet medical needs, with its first product being JATENZO, a testosterone therapy.

Clarus Therapeutics (Nasdaq:CRXT) announced the closure of a private placement, raising approximately $15 million to support the commercialization of its oral testosterone replacement therapy, JATENZO®. The company sold 3,024,194 units at $4.96 per unit, each consisting of one share of common stock and a five-year warrant with an exercise price of $5.25. The securities were privately placed and not registered under the Securities Act, although Clarus plans to file for a resale registration with the SEC.

Clarus Therapeutics Holdings (CRXT) announced a definitive agreement for a private placement, aiming to raise approximately $15 million to support the commercialization of its testosterone replacement product, JATENZO. The placement involves issuing 3,024,194 units at $4.96 each, with warrants exercisable at $5.25 per share. The private placement is expected to close by December 7, 2021. The proceeds will bolster growth initiatives for JATENZO, addressing unmet medical needs in testosterone therapy.

Clarus Therapeutics Holdings announced the issuance of two new patents for its oral testosterone replacement therapy, JATENZO, enhancing its patent portfolio and bringing the total number of Orange Book-listed patents to seven. The new patents, 11,179,403 and 11,179,402, extend protection until 2030 and 2026 respectively. This reinforces the intellectual property for JATENZO, which addresses male hypogonadism affecting around 20 million men in the U.S. The patents aim to bolster life cycle management strategies of JATENZO.

Clarus Therapeutics Holdings reported a 93% increase in third quarter revenue, reaching $4.3 million compared to $2.2 million the previous year. Prescription growth for JATENZO® rose 12% sequentially and 132% year-over-year. The company achieved milestones like settling patent litigation with Lipocine and securing licensing agreements with McGill University and HavaH Therapeutics. However, the net loss widened to $2.8 million from a net income of $5.4 million in the prior year. Operating expenses decreased by 7.6%, while cash holdings were $22 million as of September 30, 2021.

Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT) announced it will release its third quarter 2021 financial and operating results on November 18, 2021, after market close. A conference call will follow at 5:15 p.m. ET to discuss these results. Domestic callers can dial (844) 249-2007, while international callers should use (224) 619-3902; the conference ID is 1354439. The call will also be available as a live webcast on the company's Investors section.

Clarus Therapeutics has received two notices of allowance from the USPTO for patents related to its oral testosterone product, JATENZO® (testosterone undecanoate). These patents, expected to expire in 2030 and 2026, will enhance JATENZO's intellectual property portfolio, bringing the total number of patents to seven. JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in men with testosterone deficiency due to specific medical conditions, affecting an estimated 20 million men in the U.S.

Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT) announced new real-world data for JATENZO® (testosterone undecanoate), the first FDA-approved oral testosterone replacement therapy for adult males with testosterone deficiency. This data will be presented at the 22nd Annual Fall Scientific Meeting of the Sexual Medicine Society of North America from October 21-24, 2021. An estimated 20 million men in the U.S. have male hypogonadism, a condition impacting testosterone production, with JATENZO as a therapeutic option. The abstract presentation is scheduled for October 21, 2021, at 4:20 PM MST.

Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT) is set to present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:40 a.m. ET. The presentation will focus on the company's commitment to addressing unmet medical needs through androgen and metabolic therapies. Investors can access the live webcast via the Investors section of the Clarus Therapeutics website, with an archived version available for 90 days post-presentation. Clarus's flagship product is JATENZO®, aimed at providing innovative solutions.